A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...

Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Some jellyfish possess the extraordinary ability to revert their cells back to an earlier developmental stage, effectively ...

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the close of a ...

Scientists at the Salk Institute for Biological Studies and Sanford Burnham Prebys explore genetic factors in separate papers ...